Latest News Feed
IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world
Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology
- New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models -
- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings -
- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics -
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function -
- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy -
Innovative use of geofencing technology boosts enrollment at select sites
New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease
Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's